Denosumab for Patients With Persistent or Relapsed Hypercalcemia of Malignancy Despite Recent Bisphosphonate Treatment

Hypercalcemia of malignancy (HCM), caused primarily by tumor-induced bone resorption, may lead to renal failure, coma, and death. Although HCM can be treated with intravenous bisphosphonates, patients may not respond or may relapse on therapy. Denosumab binds the bone resorption mediator RANKL. In t...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Hu, Mimi I., Glezerman, Ilya, Leboulleux, Sophie, Insogna, Karl, Gucalp, Rasim, Misiorowski, Waldemar, Yu, Bennett, Ying, Wendy, Jain, Rajul K.
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2013
Assuntos:
Brief Communication
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3776443/
https://ncbi.nlm.nih.gov/pubmed/23990665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djt225
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares